Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Janet Dorling Biography and Net Worth

Director of CymaBay Therapeutics

Janet Dorling has been a member of our Board of Directors since April 2021. Ms. Dorling has been the Senior Vice President, Intercontinental Region and Global Patient Solutions at Gilead Sciences, Inc. Since July 2023. Previously, Ms. Dorling was Senior Vice President, Global Commercial Product Strategy at Gilead Sciences Inc. from May 2020 to July 2023. She was the Chief Commercial Officer at CymaBay Therapeutics, Inc. from August 2019 to December 2019 and the Chief Commercial Officer at Achaogen from 2017 to 2019. Previously she served as Vice President, Breast Cancer Franchise, Global Product Strategy from 2015 to 2017 at Roche and from 2007 through 2015 served in various marketing and commercial roles at Genentech. Ms. Dorling received a M.S. from Duke University and an M.B.A. from the University of California, Berkeley.

How do I contact Janet Dorling?: The corporate mailing address for Ms. Dorling and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Janet Dorling's contact information.
Has Janet Dorling been buying or selling shares of CymaBay Therapeutics?: Janet Dorling has not been actively trading shares of CymaBay Therapeutics during the last ninety days. Most recently, Janet Dorling sold 6,000 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $31.97, for a transaction totalling $191,820.00. Learn More on Janet Dorling's trading history.
Who are CymaBay Therapeutics' active insiders?: CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.
Are insiders buying or selling shares of CymaBay Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.
Information on this page was last updated on 2/12/2024.

Janet Dorling Insider Trading History at CymaBay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/12/2024	Sell	6,000	$31.97	$191,820.00
1/10/2024	Sell	6,000	$23.86	$143,160.00
12/11/2023	Sell	6,000	$20.07	$120,420.00

Janet Dorling Buying and Selling Activity at CymaBay Therapeutics

CymaBay Therapeutics Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Today's Range

Now: $32.48

$32.48

50 Day Range

MA: $32.40

$32.17

$32.48

2 Week Range

Now: $32.48

$7.26

$32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32